ClinicalTrials.gg
CompletedNCT05417867Updated Oct 29, 2026

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

An observational study in Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma and Anatomic Stage I Breast Cancer AJCC v8, sponsored by Mayo Clinic. Completed at 5 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Mayo Clinic · Observational

How we know

Updated Oct 29, 2026Now CompletedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
47
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 160 studies in Breast Neoplasms by Mayo Clinic — 30 open to participants now, 41 under way, 1 of them phase 3. Breast Neoplasms · Mayo Clinic.

Enrollment
38th of 62
47 · median 95
Started
2021
with 7 others
Observational
62 of 160
9 open now
Registered
116th of 160
by date

Among the 160 studies in Breast Neoplasms by Mayo Clinic, this one is the 38th largest by enrollment of the 62 observational ones that give a count, is one of 8 that started in 2021, is one of 62 observational ones, and was the 116th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 160 studies in Breast Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Breast Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of fatigue and chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for early stage breast cancer. Patients undergoing chemotherapy may experience fatigue or nausea as a result of their treatment. Known risk factors for fatigue and CIN do not explain the differences in fatigue and CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of fatigue and CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with fatigue and CIN.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of patient recruitment and retention, as well as specimen collection.

II. Estimate the effect size for changes in gut microbiome composition profiles and metabolites in stool as well as blood from time of first stool sample collection prior to chemotherapy (T1) to time of second stool sample collection after chemotherapy (T2) that are associated with the occurrence of fatigue and CIN.

III. Evaluate associations between patient reported demographic and clinical characteristics, comorbidities at T1, and changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 with the occurrence of fatigue and CIN.

OUTLINE: This is an observational study.

Patients undergo collection of stool and blood samples and complete questionnaires on study.

03

Conditions studied

  • Chemotherapy-Related Nausea and/or Vomiting
  • Early Stage Breast Carcinoma
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with a diagnosis of early stage breast cancer, planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic Health Systems including Mankato and Albert Lea, Mayo Clinic Arizona, Mayo Clinic, Minnesota, and Mayo Clinic Florida.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of early stage breast cancer planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic Health Systems including Mankato and Albert Lea; Mayo Clinic Arizona; Mayo Clinic Rochester (Minnesota); and Mayo Clinic Florida
  • At least 20 years of age
  • Last chemotherapy more than 3 years ago
  • Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies

Exclusion criteria

Exclusion Criteria:

  • disease
  • Concurrent radiation therapy
  • Concurrent antibiotic treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
47 participants (actual)
Patient registry
No

Groups and cohorts

  • Observational

    Patients undergo collection of stool and blood samples and complete questionnaires on study.

    Procedure: Biospecimen Collection · Other: Questionnaire Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of stool and blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OtherQuestionnaire Administration

    Complete questionnaires

06

What researchers measure

Primary outcomes

  1. Number of patients approached

    Assessed using descriptive statistics.

    Time frame: Up to 24 months

  2. Number of patients enrolled

    Assessed using descriptive statistics.

    Time frame: Up to 24 months

  3. Number of patients who completed the questionnaires at both assessments

    Assessed using descriptive statistics.

    Time frame: At baseline and 3-5 days after initiation of chemotherapy

  4. Number of patients who provided stool samples at both assessments

    Assessed using descriptive statistics.

    Time frame: At baseline and 3-5 days after initiation of chemotherapy

  5. Bacterial composition of stool samples

    All stool samples will be processed for deoxyribonucleic acid extraction. The hypervariable regions V3 and V4 of the bacterial 16S ribosomal ribonucleic acid (rRNA) gene will be sequenced to determine bacterial composition. After quality control, 16S rRNA reads will be analyzed to determine operational taxonomic units (OTU) for T1 and T2 samples using QIIME software. Alpha (within sample) diversity and beta (between sample) diversity will be analyzed using nonmetric multidimensional scaling ordination and the effect size for changes in OTUs in gut microbiome composition profiles from T1 to T2 in patients who do and do not report fatigue or chemotherapy-induced nausea (CIN) at T2 as measured by questionnaire.

    Time frame: Up to study completion, approximately 1 month

  6. Differences in demographic between patients who do and do not report fatigue and CIN

    Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of fatigue and CIN will be evaluated.

    Time frame: Up to study completion, approximately 1 month

  7. Differences in clinical characteristics between patients who do and do not report CIN

    Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated.

    Time frame: Up to study completion, approximately 1 month

  8. Differences in comorbidities between patients who do and do not report CIN

    Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated.

    Time frame: Up to study completion, approximately 1 month

07

Study locations

5 sites
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224-9980, United States
  • Mayo Clinic Health System in Albert Lea
    Albert Lea, Minnesota 56007, United States
  • Mayo Clinic Health System in Mankato
    Mankato, Minnesota 56001, United States
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jul 2025, 45 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 45 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Apr 2021 → Oct 2021, primary completion Sep 2026 → Jul 2025 and completion Mar 2027 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 14, 2022
StartActual
Oct 6, 2021was Apr 2021
Primary completionActual
Jul 13, 2025was Sep 2026
CompletionActual
Jul 13, 2025was Mar 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Start date
Apr 14, 2021→Oct 6, 2021
Oct 29, 2026
Primary completion
Sep 30, 2026→Jul 13, 2025 (actual)
Oct 29, 2026
Study completion
Mar 31, 2027→Jul 13, 2025 (actual)
Oct 29, 2026
Enrollment
70 (estimated)→47 (actual)
Oct 29, 2026
Primary outcomes
4 time frame changed
What changed in the outcomes
  • Time frameBacterial composition of stool samplesUp to study completion → Up to study completion, approximately 1 month
  • Time frameDifferences in demographic between patients who do and do not report fatigue and CINUp to study completion → Up to study completion, approximately 1 month
  • Time frameDifferences in clinical characteristics between patients who do and do not report CINUp to study completion → Up to study completion, approximately 1 month
  • Time frameDifferences in comorbidities between patients who do and do not report CINUp to study completion → Up to study completion, approximately 1 month
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Start date Apr 14, 2021→Oct 6, 2021
    Primary completion Sep 30, 2026→Jul 13, 2025 (now actual)
    Study completion Mar 31, 2027→Jul 13, 2025 (now actual)
    Enrollment 70 (estimated)→47 (actual)
    Primary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameBacterial composition of stool samplesUp to study completion → Up to study completion, approximately 1 month
    • Time frameDifferences in demographic between patients who do and do not report fatigue and CINUp to study completion → Up to study completion, approximately 1 month
    • Time frameDifferences in clinical characteristics between patients who do and do not report CINUp to study completion → Up to study completion, approximately 1 month
    • Time frameDifferences in comorbidities between patients who do and do not report CINUp to study completion → Up to study completion, approximately 1 month
    + 3 other changes: verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05417867
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Oct 6, 2021
Primary completion
Jul 13, 2025
Completion
Jul 13, 2025
Last update
Oct 29, 2026

Study contacts

Brenda J. Ernst, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion